Cargando…
Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia
Until recently, treatment advances in acute myeloid leukemia (AML) had been slow since the 1970s. However, in the past few years, as the understanding of the pathophysiology of AML has advanced, numerous treatments have been approved by the U.S. Food & Drug Administration. This article reviews t...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Harborside Press LLC
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521119/ https://www.ncbi.nlm.nih.gov/pubmed/33537166 http://dx.doi.org/10.6004/jadpro.2019.10.8.13 |